Ara Parlakian

Ara Parlakian

Auto-generated profile, based on publicly available information

Ara Parlakian

Institut de Biologie Paris-Seine (IBPS), CNRS UMR 8263, Inserm U1345, Development, Adaptation and Ageing, Sorbonne Université, Paris, France

Research Focus & Metrics

Academic Career Length

27Years (2000-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
31 January 2010 in Nature Cell Biology
Verified
Journal Article
Closed access
KMKathryn J. Mitchell
Kathryn J. Mitchell
APAlice Pannérec
Alice Pannérec
BCBruno Cadot
Bruno Cadot
APAra Parlakian
Ara Parlakian
VBVanessa Besson
Vanessa Besson
DSDavid A. Sassoon
David A. Sassoon

1 June 2004 in Molecular and Cellular Biology
Verified
Journal Article
Open access
PDF file
APAra Parlakian
Ara Parlakian
DTDavid Tuil
David Tuil
GHGhislaine Hamard
Ghislaine Hamard
GTGeneviève Tavernier
Geneviève Tavernier
DHDaniele Hentzen
Daniele Hentzen
DDDominique Daegelen
Dominique Daegelen
Serum response factor (SRF) is at the confluence of multiple signaling pathways controlling the transcription of immediate-early response genes and muscle-specific genes. There are active SRF target sequences in more than 50 genes expressed in the three muscle lineages including normal and diseased hearts. However, the role of SRF in heart formation has not been addressed in vivo thus far due to the early requirement of SRF for mesoderm formation. We have generated a conditional mutant of SRF by using Cre-LoxP strategy that will be extremely useful to study the role of SRF in embryonic and postnatal cardiac functions, as well as in other tissues. This report shows that heart-specific deletion of SRF in the embryo by using a new βMHC-Cre transgenic mouse line results in lethal cardiac defects between embryonic day 10.5 (E10.5) and E13.5, as evidenced by abnormally thin myocardium, dilated cardiac chambers, poor trabeculation, and a disorganized interventricular septum. At E9.5, we found a marked reduction in the expression of essential regulators of heart development, including Nkx2.5, GATA4, myocardin, and the SRF target gene c-fos prior to overt maldevelopment. We conclude that SRF is crucial for cardiac differentiation and maturation, acting as a global regulator of multiple developmental genes.

8 November 2005 in Circulation
Verified
Journal Article
Closed access
PDF file
APAra Parlakian
Ara Parlakian
CCClaude L Charvet
Claude L Charvet
BEBrigitte Escoubet
Brigitte Escoubet
Mathias MERICSKAYMathias MERICSKAY
Mathias MERICSKAY
JMJeffery D Molkentin
Jeffery D Molkentin
ZLZhenlin Li
Zhenlin Li
Background— Serum response factor (SRF) is a cardiac transcription factor involved in cell growth and differentiation. We have shown, using the Cre/loxP system, that cardiac-specific disruption of SRF gene in the embryonic heart results in lethal cardiac defects. The role of SRF in adult heart is unknown. Methods and Results— We disrupted SRF in the adult heart using a heart-specific tamoxifen-inducible Cre recombinase. This disruption led to impaired left ventricular function with reduced contractility, subsequently progressing to dilated cardiomyopathy, as demonstrated by serial echocardiography, including tissue Doppler imaging. The cytoarchitecture of cardiomyocytes was altered in the intercalated disks. All mutant mice died from heart failure 10 weeks after treatment. These functional and structural defects were preceded by early alterations in the cardiac gene expression program: major decreases in mRNA levels for cardiac α-actin, muscle creatine kinase, and calcium-handling genes. Conclusions— SRF is crucial for adult cardiac function and integrity. We suggest that the rapid progression to heart failure in SRF mutant mice results primarily from decreased expression of proteins involved in force generation and transmission, low levels of polymerized actin, and changes in cytoarchitecture, without hypertrophic compensation. These cardiac-specific SRF-deficient mice have the morphological and clinical features of acquired dilated cardiomyopathy in humans and may therefore be used as an inducible model of this disorder.

12 July 2013 in Proceedings of the National Academy of Sciences
Verified
Journal Article
Open access
PDF file
TCThomas Cherrier
Thomas Cherrier
VDValentin Le Douce
Valentin Le Douce
SESebastian Eilebrecht
Sebastian Eilebrecht
RRRaphael Riclet
Raphael Riclet
CMCéline Marban
Céline Marban
OROlivier ROHR
Olivier ROHR
The positive transcription elongation factor b (P-TEFb) is involved in physiological and pathological events including inflammation, cancer, AIDS, and cardiac hypertrophy. The balance between its active and inactive form is tightly controlled to ensure cellular integrity. We report that the transcriptional repressor CTIP2 is a major modulator of P-TEFb activity. CTIP2 copurifies and interacts with an inactive P-TEFb complex containing the 7SK snRNA and HEXIM1. CTIP2 associates directly with HEXIM1 and, via the loop 2 of the 7SK snRNA, with P-TEFb. In this nucleoprotein complex, CTIP2 significantly represses the Cdk9 kinase activity of P-TEFb. Accordingly, we show that CTIP2 inhibits large sets of P-TEFb- and 7SK snRNA-sensitive genes. In hearts of hypertrophic cardiomyopathic mice, CTIP2 controls P-TEFb-sensitive pathways involved in the establishment of this pathology. Overexpression of the β-myosin heavy chain protein contributes to the pathological cardiac wall thickening. The inactive P-TEFb complex associates with CTIP2 at the MYH7 gene promoter to repress its activity. Taken together, our results strongly suggest that CTIP2 controls P-TEFb function in physiological and pathological conditions.

1 September 2008 in Developmental Cell
Verified
Journal Article
Closed access
CFClaudio Areias Franco
Claudio Areias Franco
Mathias MERICSKAYMathias MERICSKAY
Mathias MERICSKAY
APAra Parlakian
Ara Parlakian
GGGuillaume Gary-Bobo
Guillaume Gary-Bobo
JGJacqueline Gao-Li
Jacqueline Gao-Li
ZLZhenlin Li
Zhenlin Li

1 June 2013 in Development
Verified
Journal Article
Closed access
PDF file
CFClaudio A. Franco
Claudio A. Franco
JBJocelyne Blanc
Jocelyne Blanc
APAra Parlakian
Ara Parlakian
RBRaquel Blanco
Raquel Blanco
IAIrene M. Aspalter
Irene M. Aspalter
ZLZhenlin Li
Zhenlin Li
Efficient angiogenic sprouting is essential for embryonic, postnatal and tumor development. Serum response factor (SRF) is known to be important for embryonic vascular development. Here, we studied the effect of inducible endothelial-specific deletion of Srf in postnatal and adult mice. We find that endothelial SRF activity is vital for postnatal growth and survival, and is equally required for developmental and pathological angiogenesis, including during tumor growth. Our results demonstrate that SRF is selectively required for endothelial filopodia formation and cell contractility during sprouting angiogenesis, but seems dispensable for vascular remodeling. At the molecular level, we observe that vascular endothelial growth factor A induces nuclear accumulation of myocardin-related transcription factors (MRTFs) and regulates MRTF/SRF-dependent target genes including Myl9, which is important for endothelial cell migration in vitro. We conclude that SRF has a unique function in regulating migratory tip cell behavior during sprouting angiogenesis. We hypothesize that targeting the SRF pathway could provide an opportunity to selectively target tip cell filopodia-driven angiogenesis to restrict tumor growth.